Similarly, checkpoint inhibitors like ipilimumab, nivolumab, pembrolizumab, and intrathecal interleukin-2 (IL-2) show promise in the treatment of LMM, but the evidence is limited. The gene discussed is IL2; the disease is lentigo maligna melanoma.